MEDAG

Across TCGA pan-cancer cohorts, MEDAG Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MEDAG data layer compared with 25 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MEDAG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEDAG expression acts as an unfavorable survival marker.

MESO, LUSC, and LIHC are the cancer types where MEDAG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
LIHC	DFS	Median	All	0.045	0.553	<.001	15	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MEDAG–MESO (OS)

Open the MESO breakdown →